Page 60 - 2021_02-Haematologica-web

E. Wagner-Drouet et al. Haematol. 2018;101(1):38-47.
50. Lilleri D, Fornara C, Chiesa A, et al. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica. 2008;93(2):248-256.
51. Ozdemir E, St John LS, Gillespie G, et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associ- ated with the presence of dysfunctional anti-
gen-specific CD8+ T cells. Blood.
2002;100(10):3690-3697.
52. Jung J, Lee H-J, Kim S-M, et al. Diagnostic
usefulness of dynamic changes of CMV-spe- cific T-cell responses in predicting CMV infections in HCT recipients. J Clin Virol. 2017;87:5-11.
53. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377 (25):2433-2444.
54. Lindemann M, Eiz-Vesper B, Steckel NK, et al. Adoptive transfer of cellular immunity against cytomegalovirus by virus-specific lymphocytes from a third-party family donor. Bone Marrow Transplant. 2018;53 (10):1351-1355.
55.Chemaly RF, Chou S, Einsele H, et al. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 2019;68(8):1420-1426.
374
haematologica | 2021; 106(2)